Publicacións en colaboración con investigadores/as de Hospital de Gran Canaria Dr. Negrin (30)

2025

  1. Genome-wide association study of susceptibility to acute respiratory distress syndrome

    eBioMedicine, Vol. 120

  2. [Translated article] Clinical–Epidemiological Profile, and Treatment Response in Relation to Associated Atopic Comorbidity in Atopic Dermatitis. Experience From the BIOBADATOP Registry

    Actas Dermo-Sifiliograficas, Vol. 116, Núm. 4, pp. T337-T348

  3. [Translated article] Clinical–Epidemiological Profile, and Treatment Response in Relation to Associated Atopic Comorbidity in Atopic Dermatitis. Experience From the BIOBADATOP Registry

    Actas Dermo-Sifiliograficas

2024

  1. Clinical-Epidemiological Profile, and Treatment Response in Relation to Associated Atopic Comorbidity in Atopic Dermatitis. Experience From the BIOBADATOP Registry

    Actas Dermo-Sifiliograficas

  2. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 4, pp. 341-346

  3. Melanoma Registry of the Spanish Academy of Dermatology and Venereology (REGESMEL): Description and Data in its First Year of Operation

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 663-669

  4. Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 9, pp. 906-911

  5. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  2. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

    Actas Dermo-Sifiliograficas

  3. Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))

    Nature communications

  4. Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 571-575

  5. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  6. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas

  7. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T479-T487

2022

  1. A genome-wide association study of survival in patients with sepsis

    Critical Care, Vol. 26, Núm. 1

  2. New insights into the genetic etiology of Alzheimer's disease and related dementias

    Nature genetics, Vol. 54, Núm. 4, pp. 412-436

  3. Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14

  4. Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29

  5. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola